Manufacturer: Cipla, India
Pharmaceutical name: Lamivudine
Pack: 10 pills (100 mg)
Lamivir HBV is a nucleoside analogue prescribed in conjunction with other antiretroviral medications for treating human immunodeficiency virus (HIV-1) infection.
For adults and adolescents over 16 years of age infected with HIV-1, the suggested oral dosage of Lamivir HBV is 300 mg per day, which can be taken as either 150 mg twice daily or 300 mg once daily alongside other antiretroviral drugs. When Lamivudine is given to a patient with both HIV-1 and HBV, the dosage intended for HIV-1 treatment should be part of a suitable combination therapy.
In pediatric patients aged 3 months to 16 years infected with HIV-1, the recommended oral dose of Lamivir HBV is 4 mg/kg twice daily (up to a maximum of 150 mg twice daily), in conjunction with other antiretroviral therapies.
Lamivir HBV has the potential to cause severe inflammation of the pancreas (pancreatitis), which can be life-threatening. It is crucial to inform your healthcare provider immediately if you experience any symptoms of pancreatitis, such as: a painful or swollen abdomen; nausea and vomiting; fever; a rapid heartbeat (tachycardia); or rapid breathing.
Rarely, Lamivir HBV may lead to a condition known as lactic acidosis and hepatic steatosis, resulting from liver damage and potentially severe complications. Individuals with existing liver disease have a greater risk of experiencing this side effect.
The kidneys play a role in eliminating Lamivir HBV from the body. If you have kidney issues, your healthcare provider may need to keep a closer watch on you and might suggest a reduced dosage of lamivudine.
Lamivir HBV can alter fat distribution in the body, potentially causing weight gain in unexpected areas, such as the abdomen or at the nape of the neck (commonly referred to as a "buffalo hump"), while leading to weight loss in other regions.